Cyclophosphamide
Pembrolizumab
Cancer Institute and Hospital, Chinese Academy of Medical SciencesSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 89/ 100
Competitive context
5 Active assets in the Pembrolizumab cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Pembrolizumab Ismail Gögenur | Phase 2 | B |
LENVATINIB National Taiwan University Hospital | Phase 2 | B |
Mirabegron Obstetrics & Gynecology Hospital of Fudan University | Phase 2 | CCC |
Epirubicin Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 2 | CCC |
Sitravatinib Sarah Goldberg | Phase 2 | CCC |
Same molecule, other indications
Cyclophosphamide is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →